Jaguar Health Inc.

12/18/2024 | Press release | Distributed by Public on 12/18/2024 09:04

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.